Amphastar receives fda tentative approval for vasopressin

Rancho cucamonga, ca / accesswire / december 29, 2021 / amphastar pharmaceuticals, inc. (nasdaq:amph) announced that the u.s. food and drug administration ("fda") has tentatively approved the company's abbreviated new drug application ("anda") for vasopressin injection, usp 20 units/ml, 1ml single dose vial. vasopressin is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
AMPH Ratings Summary
AMPH Quant Ranking